BAUSCH HEALTH AMERICAS, INC.
🇺🇸United States
Mesalamine Pellet Formulation to Maintain Remission of Mild to Moderate Ulcerative Colitis
- First Posted Date
- 2008-08-29
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 305
- Registration Number
- NCT00744016
Open-Label Study to Evaluate the Effect of Rifaximin on Midazolam in Normal Healthy Volunteers
- First Posted Date
- 2008-08-29
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00743912
Rifaximin for Prevention of Travellers' Diarrhea
- First Posted Date
- 2008-08-27
- Last Posted Date
- 2019-12-18
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 210
- Registration Number
- NCT00742469
- Locations
- 🇲🇽
University of San Diego, Guadalajara, Jalisco, Mexico
Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-08-11
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 623
- Registration Number
- NCT00731679
Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-07-29
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 637
- Registration Number
- NCT00724126
Evaluation of Irritation That Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face.
- First Posted Date
- 2008-07-14
- Last Posted Date
- 2012-02-15
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT00714714
- Locations
- 🇺🇸
A J&J CPPW Investigational Site, Broomall, Pennsylvania, United States
Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 322
- Registration Number
- NCT00686920
(CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-05-16
- Last Posted Date
- 2019-12-10
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 514
- Registration Number
- NCT00679380
- Locations
- 🇧🇪
Imelda Hospital, Bonheiden, Belgium
🇦🇺The Alfred Hospital, Melbourne, Australia
🇪🇪East Viru Central Hospital, Kohtla-Jarve, Estonia
(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-05-16
- Last Posted Date
- 2019-12-10
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 510
- Registration Number
- NCT00679432
- Locations
- 🇺🇸
Santarus Clinical Investigational Site 5005, Marlton, New Jersey, United States
🇮🇳Santarus Clinical Investigational Site 9018, Rajasthan, India
🇲🇽Santarus Clinical Investigational Site 7000, Colonia Centra, La Paz Baja California Sur, Mexico
Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness
- First Posted Date
- 2008-05-06
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 156
- Registration Number
- NCT00672139
- Locations
- 🇬🇧
Salix Investigational Site, Cheltenham, Gloucestershire, United Kingdom
🇲🇽Pfizer Investigational Site, Mexico City DF, Mexico
© Copyright 2024. All Rights Reserved by MedPath